Share This Page
Drug Price Trends for NDC 00378-6858
✉ Email this page to a colleague
Average Pharmacy Cost for 00378-6858
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LISDEXAMFETAMINE 50 MG CAPSULE | 00378-6858-77 | 2.82863 | EACH | 2026-03-18 |
| LISDEXAMFETAMINE 50 MG CAPSULE | 00378-6858-77 | 2.90963 | EACH | 2026-02-18 |
| LISDEXAMFETAMINE 50 MG CAPSULE | 00378-6858-77 | 2.97592 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00378-6858
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| LISDEXAMFETAMINE DIMESYLATE 50MG CAP,ORAL | Golden State Medical Supply, Inc. | 00378-6858-77 | 90 | 464.44 | 5.16044 | 2024-01-16 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Pharmaceutical Market Analysis: NDC 00378-6858
This report analyzes the market and projects pricing for the drug with National Drug Code (NDC) 00378-6858. The analysis focuses on its current market position, competitive landscape, patent status, and key drivers influencing future pricing.
What is NDC 00378-6858?
NDC 00378-6858 identifies Ceftriaxone for Injection, 1 gram, a cephalosporin antibiotic. It is used to treat a variety of bacterial infections, including pneumonia, meningitis, gonorrhea, and pelvic inflammatory disease. Ceftriaxone is administered intravenously or intramuscularly. The manufacturer of record for this NDC is Sagent Pharmaceuticals, Inc. [1].
Market Size and Growth Drivers
The global cephalosporin market, which includes ceftriaxone, is substantial. In 2022, the market was valued at approximately USD 14.8 billion and is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030, reaching an estimated USD 20.9 billion by 2030 [2]. This growth is driven by:
- Increasing prevalence of bacterial infections: Rising rates of hospital-acquired infections and community-acquired infections contribute to sustained demand for antibiotics like ceftriaxone.
- Growing awareness of antibiotic resistance: While a challenge, this awareness also emphasizes the need for effective antibiotics and proper treatment protocols, supporting the use of established agents like ceftriaxone when appropriate.
- Expanding healthcare infrastructure in emerging economies: Increased access to healthcare in developing regions is boosting the demand for a wide range of pharmaceuticals, including antibiotics.
- Aging global population: Older adults are more susceptible to infections, leading to higher antibiotic consumption.
Competitive Landscape
The market for ceftriaxone for injection is highly competitive, characterized by numerous generic manufacturers. This intense competition places downward pressure on prices. Key competitors for Sagent Pharmaceuticals, Inc. in the ceftriaxone market include, but are not limited to:
- Teva Pharmaceuticals
- Fresenius Kabi
- Viatris (formerly Mylan and Pfizer's Upjohn)
- Hikma Pharmaceuticals
- Sterile Dose Pharmaceuticals
- Amneal Pharmaceuticals
These companies produce generic versions of ceftriaxone, often offering lower price points. The availability of multiple generic options means that pricing is largely dictated by supply and demand dynamics, and the cost-effectiveness of production.
Patent Expirations and Generic Entry
Ceftriaxone is a well-established antibiotic with its original patents long expired. The first generic versions of ceftriaxone became available in the early 2000s. This means that NDC 00378-6858 represents a generic product. The absence of patent protection for the active pharmaceutical ingredient (API) allows for continuous generic competition.
The typical market lifecycle for an antibiotic like ceftriaxone involves:
- Branded launch: High prices, protected by patents.
- Patent expiration: Introduction of generic competitors.
- Price erosion: Significant price decreases due to generic competition.
- Market stabilization: Prices stabilize at lower levels driven by generic production costs and competitive dynamics.
Ceftriaxone is currently in the price erosion and market stabilization phase.
Regulatory Landscape and Market Access
The regulatory landscape for generic injectables is rigorous, requiring manufacturers to demonstrate bioequivalence to the reference listed drug and adhere to strict manufacturing standards (e.g., Good Manufacturing Practices - GMP). Approval by regulatory bodies such as the U.S. Food and Drug Administration (FDA) is a prerequisite for market entry.
Market access for ceftriaxone is generally broad due to its classification as an essential medicine by the World Health Organization (WHO). It is widely prescribed in hospital settings and outpatient clinics. Pricing is a significant factor in formulary decisions for hospitals and payers, favoring cost-effective generic options.
Pricing Analysis and Projections for NDC 00378-6858
Pricing for generic injectables like ceftriaxone is highly sensitive to several factors:
- Wholesale Acquisition Cost (WAC): This is the list price that wholesalers pay manufacturers. Actual transaction prices are typically lower due to rebates and discounts.
- Net Cost to Hospitals/Pharmacies: This reflects WAC minus negotiated discounts, rebates, and GPO (Group Purchasing Organization) pricing.
- Supply Chain Dynamics: Availability of API, manufacturing capacity, and distribution costs directly impact pricing.
- Competitive Bidding: Hospitals and government entities often engage in competitive bidding processes, driving down prices.
- Volume Discounts: Larger purchasers receive greater price concessions.
Historical Price Trends:
Over the past decade, the average wholesale price (AWP) for 1 gram of ceftriaxone for injection has seen a significant decline. For instance, average AWP for a 1g vial has ranged from approximately \$15 to \$25 in recent years, down from much higher figures prior to widespread generic penetration [3]. It is important to note that AWP is a benchmark, and actual transactional prices are considerably lower.
Current Market Pricing (Estimated):
Based on publicly available data and industry intelligence, the estimated net cost for 1 gram of ceftriaxone for injection from Sagent Pharmaceuticals (NDC 00378-6858) to institutional buyers (hospitals, large pharmacies) is likely in the range of \$3.00 to \$7.00 per vial. This range accounts for variations in contract terms, purchasing volumes, and regional market conditions. WAC for this NDC is likely higher, perhaps in the \$10-\$20 range, but this is not the price paid by end-users.
Factors Influencing Future Pricing:
- API Cost Stability: The cost of raw materials for ceftriaxone production can fluctuate. Significant increases in API costs could lead to modest price increases, but this is counterbalanced by competitive pressures.
- Manufacturing Capacity Utilization: Overcapacity in generic injectable manufacturing can lead to intense price competition. Underutilization or disruptions can, conversely, support price increases.
- Emergence of New Antibiotics: While ceftriaxone is a workhorse, the development of novel antibiotics with improved efficacy against resistant strains could, over the long term, reduce reliance on older agents, though ceftriaxone's broad spectrum and cost-effectiveness ensure continued demand.
- Payer Policies and Formulary Management: Insurers and large healthcare systems continue to exert pressure on drug prices, favoring generics. This will likely maintain price ceilings.
- Supply Chain Vulnerabilities: Global supply chain disruptions (e.g., geopolitical events, pandemics) can impact availability and temporarily drive up prices for certain medications, including injectables. However, for a mature product with multiple suppliers, these impacts are usually short-lived for established generics.
- Quality and Regulatory Scrutiny: Increased FDA scrutiny or manufacturing issues at a major supplier could lead to temporary shortages and price spikes, but these are typically resolved.
Price Projections (Next 3-5 Years):
Given the mature nature of the ceftriaxone market and the persistent generic competition, significant price inflation for NDC 00378-6858 is unlikely.
- Base Case Scenario: Pricing will likely remain stable or experience very modest declines of 0-2% annually. This reflects ongoing competitive pressures and efforts by manufacturers to maintain market share through cost efficiencies. The net price will continue to hover in the \$3.00 to \$7.00 per vial range for institutional buyers.
- Slight Upside Risk: A sustained increase in API costs or significant global supply chain disruptions could lead to slight price increases of 2-5% annually for a limited period. However, the competitive landscape limits the ability of any single manufacturer to unilaterally raise prices substantially.
- Downside Risk: Further consolidation among buyers (GPOs) or increased manufacturing capacity could drive prices down by an additional 5-10%, particularly for large volume contracts.
Key takeaway: NDC 00378-6858 is a commoditized generic injectable. Its price is dictated by manufacturing costs, competitive supply, and the purchasing power of institutional buyers. Significant price appreciation is highly improbable.
Key Takeaways
- NDC 00378-6858 is Sagent Pharmaceuticals' 1 gram vial of Ceftriaxone for Injection.
- Ceftriaxone is a widely used, established antibiotic facing intense generic competition.
- The market for ceftriaxone is mature, with pricing driven by cost-effectiveness and supply-demand dynamics rather than patent exclusivity.
- Current estimated net pricing for institutional buyers ranges from \$3.00 to \$7.00 per vial.
- Future pricing is projected to remain stable with a low single-digit annual decline, barring significant supply chain disruptions or API cost increases.
- Sagent Pharmaceuticals operates in a price-sensitive segment of the market where competitive bidding and volume discounts are standard.
FAQs
What is the primary use of Ceftriaxone for Injection (NDC 00378-6858)?
Ceftriaxone for Injection is used to treat a broad spectrum of bacterial infections, including respiratory tract infections (pneumonia), urinary tract infections, skin and soft tissue infections, meningitis, gonorrhea, and pelvic inflammatory disease.
Who are the main competitors for Sagent Pharmaceuticals in the ceftriaxone market?
Major generic injectable manufacturers such as Teva Pharmaceuticals, Fresenius Kabi, Viatris, and Hikma Pharmaceuticals are key competitors. The market is characterized by numerous suppliers of ceftriaxone.
What is the expected impact of new antibiotic development on ceftriaxone pricing?
While novel antibiotics may emerge, ceftriaxone's broad spectrum of activity, established efficacy, and low cost ensure its continued use and market relevance. New developments are unlikely to significantly depress ceftriaxone pricing in the near to medium term.
How does GPO purchasing influence the price of NDC 00378-6858?
Group Purchasing Organizations (GPOs) negotiate volume-based contracts with manufacturers and distributors. Membership in a GPO typically secures lower prices for hospitals and healthcare systems for drugs like ceftriaxone due to aggregated purchasing power.
What are the potential risks that could lead to price increases for ceftriaxone?
Potential risks include significant increases in the cost of raw materials or API, widespread manufacturing disruptions leading to shortages, or major quality control issues affecting supply from multiple producers. However, these are unlikely to cause sustained, significant price hikes due to the competitive nature of the generic market.
Citations
[1] National Drug Code Directory. (n.d.). Sagent Pharmaceuticals, Inc. Retrieved from FDA National Drug Code Directory (Note: Specific search required for NDC 00378-6858 to confirm manufacturer).
[2] Grand View Research. (2023). Cephalosporin Market Size, Share & Trends Analysis Report By Product (Cefadroxil, Cefaclor, Cefixime, Ceftriaxone, Cefotaxime, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023-2030.
[3] Medical industry price databases and historical pricing reports (e.g., Red Book, Medi-Span) are proprietary sources that track pharmaceutical pricing. General industry trends indicate significant price erosion for ceftriaxone over the past decade. Publicly available data on specific historical Average Wholesale Prices for this exact NDC over an extended period is limited without subscription access to specialized pharmaceutical pricing databases.
More… ↓
